BRD3308
规格
| Cas Number | 1550053-02-5 |
| 规格或纯度 | ≥97% |
| 纯度 | ≥97% |
| 包装 | 50mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 57 mg/mL (198.4 mM); Water: Insoluble; Ethanol: Insoluble; |
| 简短描述 | HDAC3 选择性抑制剂 |
| 英文简短描述 | HDAC3 Selective Inhibitors |
| 过滤标签 | 表观遗传学,HDAC,HIV,Cell Cycle/DNA Damage,Anti-infection |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | BRD3308 是一种强效、高选择性的 HDAC3 抑制剂，对 HDAC3、HDAC1 和 HDAC2 的 IC50 分别为 54 nM、1.26 μM 和 1.34 μM。BRD3308 可激活 HIV-1 的转录。BRD3308 可抑制炎性细胞因子（糖脂毒性应激）诱导的胰腺 β 细胞凋亡，并增加功能性胰岛素的释放。 |
| 英文描述 |
Information BRD3308 is a potant and highly selective inhibitor ofHDAC3with IC50 of 54 nM, 1.26 μM and 1.34 μM for HDAC3, HDAC1 and HDAC2, respectively. BRD3308 activates HIV-1 transcription. BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines (glucolipotoxic stress) and increases functional insulin release. Targets HDAC3 (Cell-free assay); HDAC1 (Cell-free assay); HDAC2 (Cell-free assay) 54 nM; 1.26 μM; 1.34 μM In vitro BRD3308 is a derivative of the ortho-aminoanilide HDAC inhibitor CI-994 and is developed to be highly selective for inhibition of HDAC3 with an IC50 value that is 23-fold lower for HDAC3 than for HDAC1 or 22. HDAC3 selective inhibition induces expression of HIV and exposure to BRD3308 allows the recovery of latent HIV-1 from patient cells. In vivo Selective inhibition of HDAC3 by BRD3308 prevents diabetes onset in female NOD mice. HDAC3 treatment in vivo prevents pancreatic islet infiltration and protects β-cells from apoptosis. β-cell proliferation is increased in animals treated with BRD3308. HDAC3 treatment in vivo prevents white adipose tissue infiltration in NOD mice. Cell Research(from reference) Cell lines：2D10 cells, J89 cells, THP89 cells, J-Lat 6.3 cells Concentrations：5 μM, 10 μM, 15 μM, 30 μM Incubation Time：6 h, 12 h, 18 h, 24 h |